Estimating Waning of Vaccine Effectiveness: A Simulation Study
Abstract Background Developing accurate and reliable methods to estimate vaccine protection is a key goal in immunology and public health. While several statistical methods have been proposed, their potential inaccuracy in capturing fast intraseasonal waning of vaccine-induced protection needs to be...
Saved in:
Published in | Clinical infectious diseases Vol. 76; no. 3; pp. 479 - 486 |
---|---|
Main Authors | , , |
Format | Journal Article |
Language | English |
Published |
US
Oxford University Press
08.02.2023
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Abstract
Background
Developing accurate and reliable methods to estimate vaccine protection is a key goal in immunology and public health. While several statistical methods have been proposed, their potential inaccuracy in capturing fast intraseasonal waning of vaccine-induced protection needs to be rigorously investigated.
Methods
To compare statistical methods for estimating vaccine effectiveness (VE), we generated simulated data using a multiscale, agent-based model of an epidemic with an acute viral infection and differing extents of VE waning. We apply a previously proposed framework for VE measures based on the observational data richness to assess changes of vaccine-induced protection over time.
Results
While VE measures based on hard-to-collect information (eg, the exact timing of exposures) were accurate, usually VE studies rely on time-to-infection data and the Cox proportional hazards model. We found that its extension using scaled Schoenfeld residuals, previously proposed for capturing VE waning, was unreliable in capturing both the degree of waning and its functional form and identified the mathematical factors contributing to this unreliability. We showed that partitioning time and including a time-vaccine interaction term in the Cox model significantly improved estimation of VE waning, even in the case of dramatic, rapid waning. We also proposed how to optimize the partitioning scheme.
Conclusions
While appropriate for rejecting the null hypothesis of no waning, scaled Schoenfeld residuals are unreliable for estimating the degree of waning. We propose a Cox-model–based method with a time-vaccine interaction term and further optimization of partitioning time. These findings may guide future analysis of VE waning data.
Using simulated data, we compared different measures of vaccine effectiveness for capturing the intraseasonal waning of vaccine-induced protection. We propose an extension of the Cox model based on including a time-vaccine interaction term with further optimization of partitioning time. |
---|---|
AbstractList | Using simulated data, we compared different measures of vaccine effectiveness for capturing the intraseasonal waning of vaccine-induced protection. We propose an extension of the Cox model based on including a time-vaccine interaction term with further optimization of partitioning time. Developing accurate and reliable methods to estimate vaccine protection is a key goal in immunology and public health. While several statistical methods have been proposed, their potential inaccuracy in capturing fast intraseasonal waning of vaccine-induced protection needs to be rigorously investigated. To compare statistical methods for estimating vaccine effectiveness (VE), we generated simulated data using a multiscale, agent-based model of an epidemic with an acute viral infection and differing extents of VE waning. We apply a previously proposed framework for VE measures based on the observational data richness to assess changes of vaccine-induced protection over time. While VE measures based on hard-to-collect information (eg, the exact timing of exposures) were accurate, usually VE studies rely on time-to-infection data and the Cox proportional hazards model. We found that its extension using scaled Schoenfeld residuals, previously proposed for capturing VE waning, was unreliable in capturing both the degree of waning and its functional form and identified the mathematical factors contributing to this unreliability. We showed that partitioning time and including a time-vaccine interaction term in the Cox model significantly improved estimation of VE waning, even in the case of dramatic, rapid waning. We also proposed how to optimize the partitioning scheme. While appropriate for rejecting the null hypothesis of no waning, scaled Schoenfeld residuals are unreliable for estimating the degree of waning. We propose a Cox-model-based method with a time-vaccine interaction term and further optimization of partitioning time. These findings may guide future analysis of VE waning data. Abstract Background Developing accurate and reliable methods to estimate vaccine protection is a key goal in immunology and public health. While several statistical methods have been proposed, their potential inaccuracy in capturing fast intraseasonal waning of vaccine-induced protection needs to be rigorously investigated. Methods To compare statistical methods for estimating vaccine effectiveness (VE), we generated simulated data using a multiscale, agent-based model of an epidemic with an acute viral infection and differing extents of VE waning. We apply a previously proposed framework for VE measures based on the observational data richness to assess changes of vaccine-induced protection over time. Results While VE measures based on hard-to-collect information (eg, the exact timing of exposures) were accurate, usually VE studies rely on time-to-infection data and the Cox proportional hazards model. We found that its extension using scaled Schoenfeld residuals, previously proposed for capturing VE waning, was unreliable in capturing both the degree of waning and its functional form and identified the mathematical factors contributing to this unreliability. We showed that partitioning time and including a time-vaccine interaction term in the Cox model significantly improved estimation of VE waning, even in the case of dramatic, rapid waning. We also proposed how to optimize the partitioning scheme. Conclusions While appropriate for rejecting the null hypothesis of no waning, scaled Schoenfeld residuals are unreliable for estimating the degree of waning. We propose a Cox-model–based method with a time-vaccine interaction term and further optimization of partitioning time. These findings may guide future analysis of VE waning data. Using simulated data, we compared different measures of vaccine effectiveness for capturing the intraseasonal waning of vaccine-induced protection. We propose an extension of the Cox model based on including a time-vaccine interaction term with further optimization of partitioning time. Developing accurate and reliable methods to estimate vaccine protection is a key goal in immunology and public health. While several statistical methods have been proposed, their potential inaccuracy in capturing fast intraseasonal waning of vaccine-induced protection needs to be rigorously investigated.BACKGROUNDDeveloping accurate and reliable methods to estimate vaccine protection is a key goal in immunology and public health. While several statistical methods have been proposed, their potential inaccuracy in capturing fast intraseasonal waning of vaccine-induced protection needs to be rigorously investigated.To compare statistical methods for estimating vaccine effectiveness (VE), we generated simulated data using a multiscale, agent-based model of an epidemic with an acute viral infection and differing extents of VE waning. We apply a previously proposed framework for VE measures based on the observational data richness to assess changes of vaccine-induced protection over time.METHODSTo compare statistical methods for estimating vaccine effectiveness (VE), we generated simulated data using a multiscale, agent-based model of an epidemic with an acute viral infection and differing extents of VE waning. We apply a previously proposed framework for VE measures based on the observational data richness to assess changes of vaccine-induced protection over time.While VE measures based on hard-to-collect information (eg, the exact timing of exposures) were accurate, usually VE studies rely on time-to-infection data and the Cox proportional hazards model. We found that its extension using scaled Schoenfeld residuals, previously proposed for capturing VE waning, was unreliable in capturing both the degree of waning and its functional form and identified the mathematical factors contributing to this unreliability. We showed that partitioning time and including a time-vaccine interaction term in the Cox model significantly improved estimation of VE waning, even in the case of dramatic, rapid waning. We also proposed how to optimize the partitioning scheme.RESULTSWhile VE measures based on hard-to-collect information (eg, the exact timing of exposures) were accurate, usually VE studies rely on time-to-infection data and the Cox proportional hazards model. We found that its extension using scaled Schoenfeld residuals, previously proposed for capturing VE waning, was unreliable in capturing both the degree of waning and its functional form and identified the mathematical factors contributing to this unreliability. We showed that partitioning time and including a time-vaccine interaction term in the Cox model significantly improved estimation of VE waning, even in the case of dramatic, rapid waning. We also proposed how to optimize the partitioning scheme.While appropriate for rejecting the null hypothesis of no waning, scaled Schoenfeld residuals are unreliable for estimating the degree of waning. We propose a Cox-model-based method with a time-vaccine interaction term and further optimization of partitioning time. These findings may guide future analysis of VE waning data.CONCLUSIONSWhile appropriate for rejecting the null hypothesis of no waning, scaled Schoenfeld residuals are unreliable for estimating the degree of waning. We propose a Cox-model-based method with a time-vaccine interaction term and further optimization of partitioning time. These findings may guide future analysis of VE waning data. |
Author | Ahmed, Hasan Nikas, Ariel Zarnitsyna, Veronika I |
Author_xml | – sequence: 1 givenname: Ariel surname: Nikas fullname: Nikas, Ariel – sequence: 2 givenname: Hasan surname: Ahmed fullname: Ahmed, Hasan – sequence: 3 givenname: Veronika I orcidid: 0000-0003-3096-3695 surname: Zarnitsyna fullname: Zarnitsyna, Veronika I email: vizarni@emory.edu |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/36056892$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kdFLHDEQxoMoemd98r3skxRkdbLZbBIfWg45rXDgg219DNnZrKbsJedmV_C_b_ROaaX4kJkw-c33hZkp2fbBW0IOKZxQUOwUXZOOQVHwLTKhnIm84opupztwmZeSyT0yjfE3AKUS-C7ZYxXwSqpiQr7O4-CWZnD-Lrs1_jmFNvtlEJ232bxtLQ7u0Xob41k2y27ccuwSHXx2M4zN0yey05ou2oNN3ic_L-Y_zr_ni-vLq_PZIseSsiFXosGay6ZGYUwljTJYCwWy5CW0UArRABXSYCEqXghMsSo5MovAGa2hYPvk21p3NdZL26D1Q286verT3_snHYzT_754d6_vwqOmQCtVljwpfNko9OFhtHHQSxfRdp3xNoxRFwKUYAoAEvr5b7M3l9epJYCuAexDjL1tNbrhZSrJ23XJVD9vJlUbvdlM6jl-1_Mq-3_6aE2HcfUh-Aeztp1T |
CitedBy_id | crossref_primary_10_3390_vaccines11081312 |
Cites_doi | 10.1371/journal.pbio.2006601 10.1093/ije/17.3.635 10.1007/978-1-4757-3294-8 10.1056/NEJMoa2114114 10.1016/S1473-3099(10)70262-0 10.1017/S0950268800048019 10.1093/biomet/81.3.515 10.1371/journal.pmed.1001685 10.15585/mmwr.mm7013e3 10.1056/NEJM197704142961501 10.1038/s41591-020-1083-1 10.1093/oxfordjournals.epirev.a017990 10.1002/sim.1865 10.1002/sim.9001 10.2807/ese.18.05.20390-en 10.1137/141000671 10.1056/NEJMoa2108891 10.1016/j.vaccine.2021.08.070 10.1080/21645515.2021.1968738 10.1186/s12879-018-2981-4 10.1093/cid/ciy773 10.1016/S0140-6736(04)17223-1 10.1097/QAD.0b013e32834e1ce7 10.1056/NEJMc2112981 10.1093/cid/ciy770 10.1093/infdis/jiw105 10.1093/oxfordjournals.aje.a009385 10.1016/j.vaccine.2014.06.052 10.1198/016214504000000845 10.1093/oxfordjournals.aje.a009196 |
ContentType | Journal Article |
Copyright | The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com 2022 The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. |
Copyright_xml | – notice: The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com 2022 – notice: The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM |
DOI | 10.1093/cid/ciac725 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1537-6591 |
EndPage | 486 |
ExternalDocumentID | PMC10169445 36056892 10_1093_cid_ciac725 10.1093/cid/ciac725 |
Genre | Journal Article Research Support, N.I.H., Extramural |
GrantInformation_xml | – fundername: NIAID NIH HHS grantid: U01 AI150747 – fundername: NHLBI NIH HHS grantid: U01 HL139483 – fundername: NIAID NIH HHS grantid: U01 AI144616 – fundername: ; – fundername: ; grantid: U01 HL139483; U01 AI150747; U01 AI144616 |
GroupedDBID | --- ..I .2P .GJ .I3 .ZR 08P 0R~ 1KJ 1TH 29B 2AX 2WC 36B 3O- 4.4 48X 53G 5GY 5RE 5VS 5WD 6J9 70D AABZA AACGO AACZT AAJKP AAJQQ AAMVS AANCE AAOGV AAPGJ AAPNW AAPQZ AAPXW AAQQT AARHZ AAUAY AAUQX AAVAP AAWDT AAYOK ABBHK ABDFA ABEJV ABEUO ABGNP ABIXL ABJNI ABKDP ABLJU ABNGD ABNHQ ABNKS ABOCM ABPLY ABPQP ABPTD ABQLI ABQNK ABSMQ ABTLG ABVGC ABWST ABXSQ ABXVV ABZBJ ACFRR ACGFO ACGFS ACHIC ACPQN ACPRK ACUFI ACUKT ACUTJ ACUTO ACVCV ACYHN ACZBC ADBBV ADEYI ADGZP ADHKW ADHZD ADIPN ADMTO ADNBA ADOCK ADQBN ADQXQ ADRTK ADULT ADVEK ADYVW ADZXQ AEGPL AEGXH AEJOX AEKPW AEKSI AEMDU AEMQT AENEX AENZO AEPUE AETBJ AEUPB AEWNT AEXZC AFFNX AFFQV AFFZL AFIYH AFOFC AFRAH AFSHK AFXAL AFYAG AGINJ AGKEF AGKRT AGMDO AGQXC AGSYK AGUTN AHMBA AHMMS AHXPO AI. AIAGR AIJHB AJDVS AJEEA AJNCP ALMA_UNASSIGNED_HOLDINGS ALUQC ALXQX APIBT APJGH APWMN AQDSO AQKUS AQVQM ASPBG ATGXG AVNTJ AVWKF AXUDD AZFZN BAWUL BAYMD BCRHZ BEYMZ BHONS BTRTY BVRKM BZKNY C1A C45 CDBKE CS3 CZ4 DAKXR DCCCD DIK DILTD DU5 D~K E3Z EBS EE~ EIHJH EJD EMOBN ENERS F5P F9B FECEO FEDTE FLUFQ FOEOM FOTVD FQBLK GAUVT GJXCC H13 H5~ HAR HQ3 HTVGU HVGLF HW0 HZ~ IOX IPSME J21 J5H JAAYA JBMMH JENOY JHFFW JKQEH JLS JLXEF JPM JSG JST JXSIZ KAQDR KBUDW KOP KSI KSN L7B M49 MBLQV MHKGH MJL ML0 N4W N9A NGC NOMLY NOYVH NU- NVLIB O0~ O9- OAUYM OAWHX OBFPC OCZFY ODMLO ODZKP OJQWA OJZSN OK1 OPAEJ OVD OWPYF O~Y P2P P6G PAFKI PB- PEELM PQQKQ Q1. Q5Y QBD RD5 ROX ROZ RUSNO RW1 RXO SA0 SJN TCURE TEORI TJX TMA TR2 VH1 W8F X7H Y6R YAYTL YKOAZ YXANX ZGI ~91 ~S- AAYXX AGORE AHGBF AJBYB CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM |
ID | FETCH-LOGICAL-c413t-97dcb58dbc7aa68a9acb79084540f0477d0178ac276527c765645c3ec0531b023 |
ISSN | 1058-4838 1537-6591 |
IngestDate | Thu Aug 21 18:36:20 EDT 2025 Thu Jul 10 18:12:58 EDT 2025 Thu Apr 03 07:01:17 EDT 2025 Tue Jul 01 01:18:50 EDT 2025 Thu Apr 24 23:10:36 EDT 2025 Wed Apr 02 07:04:37 EDT 2025 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 3 |
Keywords | scaled Schoenfeld residuals multiscale modeling vaccine efficacy estimating waning of vaccine effectiveness Cox proportional hazards model |
Language | English |
License | This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/pages/standard-publication-reuse-rights) https://academic.oup.com/pages/standard-publication-reuse-rights The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c413t-97dcb58dbc7aa68a9acb79084540f0477d0178ac276527c765645c3ec0531b023 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Potential conflicts of interest. The authors: No reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed. |
ORCID | 0000-0003-3096-3695 |
OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/10169445 |
PMID | 36056892 |
PQID | 2709739000 |
PQPubID | 23479 |
PageCount | 8 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_10169445 proquest_miscellaneous_2709739000 pubmed_primary_36056892 crossref_citationtrail_10_1093_cid_ciac725 crossref_primary_10_1093_cid_ciac725 oup_primary_10_1093_cid_ciac725 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2023-02-08 |
PublicationDateYYYYMMDD | 2023-02-08 |
PublicationDate_xml | – month: 02 year: 2023 text: 2023-02-08 day: 08 |
PublicationDecade | 2020 |
PublicationPlace | US |
PublicationPlace_xml | – name: US – name: United States |
PublicationTitle | Clinical infectious diseases |
PublicationTitleAlternate | Clin Infect Dis |
PublicationYear | 2023 |
Publisher | Oxford University Press |
Publisher_xml | – name: Oxford University Press |
References | Chemaitelly (2023053119100010700_ciac725-B6) 2021; 385 Haber (2023053119100010700_ciac725-B22) 2021; 17 Keehner (2023053119100010700_ciac725-B3) 2021; 385 Halloran (2023053119100010700_ciac725-B25) 1999; 21 Kissling (2023053119100010700_ciac725-B8) 2016; 21 Therneau (2023053119100010700_ciac725-B32) 2021 Lipsitch (2023053119100010700_ciac725-B15) 2019; 68 Fine (2023053119100010700_ciac725-B26) 1988; 17 Callow (2023053119100010700_ciac725-B12) 1990; 105 Durham (2023053119100010700_ciac725-B21) 1997 Belongia (2023053119100010700_ciac725-B1) 2015; 33 Fintzi (2023053119100010700_ciac725-B36) 2021; 40 Kissling (2023053119100010700_ciac725-B9) 2013; 18 Bernal J (2023053119100010700_ciac725-B5) 2021; 385 Tian (2023053119100010700_ciac725-B35) 2005; 100 Halloran (2023053119100010700_ciac725-B24) 1997; 146 R Core Team (2023053119100010700_ciac725-B30) 2018 Therneau (2023053119100010700_ciac725-B33) 2000 Minsoko (2023053119100010700_ciac725-B20) 2014; 11 Thompson (2023053119100010700_ciac725-B7) 2021; 70 Durham (2023053119100010700_ciac725-B17) 1998; 147 O’Hagan (2023053119100010700_ciac725-B34) 2012; 26 Antia (2023053119100010700_ciac725-B11) 2018; 16 Ferdinands (2023053119100010700_ciac725-B2) 2017; 64 Petrie (2023053119100010700_ciac725-B10) 2016; 214 Centers for Disease Control and Prevention (2023053119100010700_ciac725-B28) Ray (2023053119100010700_ciac725-B4) 2019; 68 Wright (2023053119100010700_ciac725-B13) 1977; 296 Bezanson (2023053119100010700_ciac725-B29) 2017; 59 Grambsch (2023053119100010700_ciac725-B23) 1994; 81 Rane (2023053119100010700_ciac725-B31) 2021; 39 Fong (2023053119100010700_ciac725-B18) 2018; 18 Olotu (2023053119100010700_ciac725-B19) 2011; 11 Alonso (2023053119100010700_ciac725-B16) 2004; 364 Davis (2023053119100010700_ciac725-B27) 2004; 23 Edridge (2023053119100010700_ciac725-B14) 2020; 26 |
References_xml | – volume: 16 start-page: e2006601 year: 2018 ident: 2023053119100010700_ciac725-B11 article-title: Heterogeneity and longevity of antibody memory to viruses and vaccines publication-title: PLoS Biol doi: 10.1371/journal.pbio.2006601 – volume: 17 start-page: 635 year: 1988 ident: 2023053119100010700_ciac725-B26 article-title: The efficacy of pertussis vaccines under conditions of household exposure. Further analysis of the 1978–80 PHLS-ERL study in 21 area health authorities in England publication-title: Int J Epidemiol doi: 10.1093/ije/17.3.635 – volume-title: Modeling survival data: extending the Cox model year: 2000 ident: 2023053119100010700_ciac725-B33 doi: 10.1007/978-1-4757-3294-8 – volume: 385 start-page: e83 year: 2021 ident: 2023053119100010700_ciac725-B6 article-title: Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar publication-title: N Engl J Med doi: 10.1056/NEJMoa2114114 – volume: 11 start-page: 102 year: 2011 ident: 2023053119100010700_ciac725-B19 article-title: Efficacy of RTS, S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5–17 months in Kenya and Tanzania: a randomised controlled trial publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(10)70262-0 – volume: 105 start-page: 435 year: 1990 ident: 2023053119100010700_ciac725-B12 article-title: The time course of the immune response to experimental coronavirus infection of man publication-title: Epidemiol Infect doi: 10.1017/S0950268800048019 – volume: 81 start-page: 515 year: 1994 ident: 2023053119100010700_ciac725-B23 article-title: Proportional hazards tests and diagnostics based on weighted residuals publication-title: Biometrika doi: 10.1093/biomet/81.3.515 – volume-title: R: a language and environment for statistical computing year: 2018 ident: 2023053119100010700_ciac725-B30 – volume: 11 start-page: e1001685 year: 2014 ident: 2023053119100010700_ciac725-B20 article-title: Efficacy and safety of the RTS, S/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites publication-title: PLoS Med doi: 10.1371/journal.pmed.1001685 – volume: 70 start-page: 495 year: 2021 ident: 2023053119100010700_ciac725-B7 article-title: Interim estimates of vaccine effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines in preventing SARS-CoV-2 infection among health care personnel, first responders, and other essential and frontline workers—eight US locations, December 2020–March 2021 publication-title: MMWR Morb Mortal Wkly Rep doi: 10.15585/mmwr.mm7013e3 – volume: 21 start-page: 13 year: 2016 ident: 2023053119100010700_ciac725-B8 article-title: I-MOVE multicentre case-control study 2010/11 to 2014/15: is there within-season waning of influenza type/subtype vaccine effectiveness with increasing time since vaccination? publication-title: Eurosurveillance – ident: 2023053119100010700_ciac725-B28 – volume: 296 start-page: 829 year: 1977 ident: 2023053119100010700_ciac725-B13 article-title: Influenza A infections in young children: primary natural infection and protective efficacy of live-vaccine-induced or naturally acquired immunity publication-title: N Engl J Med doi: 10.1056/NEJM197704142961501 – volume: 26 start-page: 1691 year: 2020 ident: 2023053119100010700_ciac725-B14 article-title: Seasonal coronavirus protective immunity is short-lasting publication-title: Nat Med doi: 10.1038/s41591-020-1083-1 – volume: 21 start-page: 73 year: 1999 ident: 2023053119100010700_ciac725-B25 article-title: Design and interpretation of vaccine field studies publication-title: Epidemiol Rev doi: 10.1093/oxfordjournals.epirev.a017990 – volume: 23 start-page: 2961 year: 2004 ident: 2023053119100010700_ciac725-B27 article-title: Estimating vaccine efficacy from household data observed over time publication-title: Stat Med doi: 10.1002/sim.1865 – volume: 40 start-page: 5983 year: 2021 ident: 2023053119100010700_ciac725-B36 article-title: Assessing vaccine durability in randomized trials following placebo crossover publication-title: Stat Med doi: 10.1002/sim.9001 – volume: 18 start-page: 33 year: 2013 ident: 2023053119100010700_ciac725-B9 article-title: Low and decreasing vaccine effectiveness against influenza A(H3) in 2011/12 among vaccination target groups in Europe: results from the I-MOVE multicentre case-control study publication-title: Eurosurveillance doi: 10.2807/ese.18.05.20390-en – volume: 59 start-page: 65 year: 2017 ident: 2023053119100010700_ciac725-B29 article-title: Julia: a fresh approach to numerical computing publication-title: Siam Rev doi: 10.1137/141000671 – volume: 64 start-page: 544 year: 2017 ident: 2023053119100010700_ciac725-B2 article-title: Intraseason waning of influenza vaccine protection: evidence from the US influenza vaccine effectiveness network, 2011–2012 through 2014–2015 publication-title: Clin Infect Dis – volume: 385 start-page: 585 year: 2021 ident: 2023053119100010700_ciac725-B5 article-title: Effectiveness of COVID-19 vaccines against the B.1.617.2 (Delta) variant publication-title: N Engl J Med doi: 10.1056/NEJMoa2108891 – year: 2021 ident: 2023053119100010700_ciac725-B32 – volume: 39 start-page: 6144 year: 2021 ident: 2023053119100010700_ciac725-B31 article-title: Durability of protection after 5 doses of acellular pertussis vaccine among 5–9 year old children in King County, Washington publication-title: Vaccine doi: 10.1016/j.vaccine.2021.08.070 – volume: 17 start-page: 4632 year: 2021 ident: 2023053119100010700_ciac725-B22 article-title: Comparing statistical methods for detecting and estimating waning efficacy of rotavirus vaccines in developing countries publication-title: Hum Vaccin Immunother doi: 10.1080/21645515.2021.1968738 – volume: 18 start-page: 84 year: 2018 ident: 2023053119100010700_ciac725-B18 article-title: Efficacy of a bivalent killed whole-cell cholera vaccine over five years: a re-analysis of a cluster-randomized trial publication-title: BMC Infect Dis doi: 10.1186/s12879-018-2981-4 – volume: 68 start-page: 1631 year: 2019 ident: 2023053119100010700_ciac725-B15 article-title: Challenges of vaccine effectiveness and waning studies publication-title: Clin Infect Dis doi: 10.1093/cid/ciy773 – volume-title: Nonparametric exploration of waning vaccine effects using survival data year: 1997 ident: 2023053119100010700_ciac725-B21 – volume: 364 start-page: 1411 year: 2004 ident: 2023053119100010700_ciac725-B16 article-title: Efficacy of the RTS, S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial publication-title: Lancet doi: 10.1016/S0140-6736(04)17223-1 – volume: 26 start-page: 123 year: 2012 ident: 2023053119100010700_ciac725-B34 article-title: Apparent declining efficacy in randomized trials: examples of the Thai RV144 HIV vaccine and South African CAPRISA 004 microbicide trials publication-title: AIDS doi: 10.1097/QAD.0b013e32834e1ce7 – volume: 385 start-page: 1330 year: 2021 ident: 2023053119100010700_ciac725-B3 article-title: Resurgence of SARS-CoV-2 infection in a highly vaccinated health system workforce publication-title: N Engl J Med doi: 10.1056/NEJMc2112981 – volume: 68 start-page: 1623 year: 2019 ident: 2023053119100010700_ciac725-B4 article-title: Intraseason waning of influenza vaccine effectiveness publication-title: Clin Infect Dis doi: 10.1093/cid/ciy770 – volume: 214 start-page: 1142 year: 2016 ident: 2023053119100010700_ciac725-B10 article-title: Modest waning of influenza vaccine efficacy and antibody titers during the 2007–2008 influenza season publication-title: J Infect Dis doi: 10.1093/infdis/jiw105 – volume: 147 start-page: 948 year: 1998 ident: 2023053119100010700_ciac725-B17 article-title: Estimation of vaccine efficacy in the presence of waning: application to cholera vaccines publication-title: Am J Epidemiol doi: 10.1093/oxfordjournals.aje.a009385 – volume: 33 start-page: 246 year: 2015 ident: 2023053119100010700_ciac725-B1 article-title: Waning vaccine protection against influenza A (H3N2) illness in children and older adults during a single season publication-title: Vaccine doi: 10.1016/j.vaccine.2014.06.052 – volume: 100 start-page: 172 year: 2005 ident: 2023053119100010700_ciac725-B35 article-title: On the Cox model with time-varying regression coefficients publication-title: J Am Stat Assoc doi: 10.1198/016214504000000845 – volume: 146 start-page: 789 year: 1997 ident: 2023053119100010700_ciac725-B24 article-title: Study designs for evaluating different efficacy and effectiveness aspects of vaccines publication-title: Am J Epidemiol doi: 10.1093/oxfordjournals.aje.a009196 |
SSID | ssj0011805 |
Score | 2.440641 |
Snippet | Abstract
Background
Developing accurate and reliable methods to estimate vaccine protection is a key goal in immunology and public health. While several... Developing accurate and reliable methods to estimate vaccine protection is a key goal in immunology and public health. While several statistical methods have... Using simulated data, we compared different measures of vaccine effectiveness for capturing the intraseasonal waning of vaccine-induced protection. We propose... |
SourceID | pubmedcentral proquest pubmed crossref oup |
SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 479 |
SubjectTerms | Computer Simulation Humans Influenza Vaccines Major Proportional Hazards Models Vaccination - methods |
Title | Estimating Waning of Vaccine Effectiveness: A Simulation Study |
URI | https://www.ncbi.nlm.nih.gov/pubmed/36056892 https://www.proquest.com/docview/2709739000 https://pubmed.ncbi.nlm.nih.gov/PMC10169445 |
Volume | 76 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3Pb9MwFLZgSIgL4jeFAUbaCZQtsxPb2WFSNToV2MqBdlRcIttxtWosm7bsMP563oudtIEKDS5W5Vpu5c95ec9-3_sI2UDupMhkGgkjHAQopojgJcwiVJi0XPMk5kgUPhyJ4ST5NE2nCym5ml1SmU37cyWv5H9QhT7AFVmy_4BsOyl0wGfAF1pAGNobYTyA5xM9Toj2v-ky5C8faYuX5e99XeJgzDwB_ev8NKh11fmDnRvdvYYi2aRnXV02tzet2z2an3j-Vx8C7DY1o3986k9Mh3opw-c7HrlUl9eec3bksAbviQ6HtOGYgfE6M7lrGWUkUi-ttelW9AVz6uVcwrbhS7Yx8aoxf9hsX8_K1hjBfrTSM6G7tbFHX_L9ycFBPh5Mx7fJHQZBAepVfPj4ub0z2lZ1wmr7pwIbE6bfgsm3wtQd_6PDaVwKLX7PkF1yOcYPyP0QK9C-B_4hueXKR-TuYciGeEx2F_hTjz89m9GAP-3gv0P7dIE-rdF_Qib7g_HeMAp6GJEFV6OKMllYk6rCWKm1UDrT1sgsVlhEcRYnUhZgXpW2TIqUSQutSFLLnUVDawDTp2StPCvdc0ILeEFm0mjmwKFOdaxjo7lhM-NiqxQXPfKuWaXchmLxqFnyI_dJCzxHxeewpD2y0Q4-9zVSVg97A8v99xFvGyhysHJ4daVLB_s9ZxLLSqHAbY8889C0E3GIyIXKWI-oDmjtAKyg3v2mnB_XldTx6CpLkvTFDX74Jbm3eC7WyVp1ceVegUNamdf1PvwFo1yNmw |
linkProvider | Flying Publisher |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Estimating+Waning+of+Vaccine+Effectiveness%3A+A+Simulation+Study&rft.jtitle=Clinical+infectious+diseases&rft.au=Nikas%2C+Ariel&rft.au=Ahmed%2C+Hasan&rft.au=Zarnitsyna%2C+Veronika+I&rft.date=2023-02-08&rft.issn=1537-6591&rft.eissn=1537-6591&rft.volume=76&rft.issue=3&rft.spage=479&rft_id=info:doi/10.1093%2Fcid%2Fciac725&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1058-4838&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1058-4838&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1058-4838&client=summon |